Modern Drug House

Established in 1962, Modern Drug House is a Mumbai-based pharmaceutical exporter specializing in the distribution of vaccines and life-saving pharmaceutical products. The company operates as a partnership firm, with an annual turnover ranging between ₹25 crore and ₹100 crore. Its registered office is located at 3-B, 1st Floor, Prime Plaza, JV Patel Compound, Balashet Madhurkar Marg, Elphinstone Road, Mumbai - 400013, Maharashtra, India.

The firm's Import Export Code (IEC) is 0312031611, and it holds FDA-approved drug licenses numbered 21B WZ 28/1609 and 20B WZ 28/1641. The company is managed by a team of professionals, including sourcing agents, medical experts, quality analyzers, and warehousing and packaging personnel.

Modern Drug House does not operate its own manufacturing facilities. Instead, it sources pharmaceutical products from a network of reputable manufacturers. The company emphasizes quality assurance by selecting vendors based on their market credibility, product quality, and financial stability. Notable authorized dealerships include Novartis, Bharat Serum, Abbott Pvt Ltd., Chiron Panacea, Kamada Pvt Ltd., Panacea Biotech, GlaxoSmithKline, Synergy India Pvt Ltd., Serum Institute of India, VHB Life Science Pvt Ltd., John Wyeth & Brother Ltd., Bio-Med Biological Pvt. Ltd., Merck Sharp & Dohme (MSD), Bharat Biotech International Pvt. Ltd., and Sanofi Pasteur Pvt. Ltd.

The leadership team at Modern Drug House includes:

• Mr. Darshan Parekh: Global Sales Director, overseeing international sales operations.

• Mr. Bharat M. Parekh: Promoter and partner, contributing to strategic decision-making.

• Mr. Atul Manilal Parekh: GST Partner, involved in financial and compliance aspects.

Modern Drug House's export activities are primarily focused on finished pharmaceutical formulations, including vaccines and injectables. The company has established a robust network of manufacturers to ensure timely distribution to both Indian and overseas customers. While specific regulatory filings and approvals in markets such as the United States, European Union, United Kingdom, Australia, and Japan are not publicly disclosed, the company's adherence to international quality standards and its partnerships with globally recognized manufacturers suggest compliance with regulatory requirements in these regions.

Modern Drug House has expanded its reach to emerging markets, including Africa, Latin America, and Southeast Asia. The company's extensive network of manufacturers and its commitment to quality assurance have facilitated its penetration into these regions. While specific details regarding WHO prequalification are not available, the company's partnerships with reputable manufacturers and its adherence to international quality standards position it favorably for access to these markets.

Modern Drug House's geographic strategy involves leveraging its partnerships with a diverse range of manufacturers to distribute pharmaceutical products across various international markets. This approach mitigates concentration risk by not relying on a single market or product line. The company's strategic direction focuses on expanding its global footprint while maintaining a strong presence in the domestic market.

Modern Drug House holds FDA-approved drug licenses numbered 21B WZ 28/1609 and 20B WZ 28/1641, indicating compliance with FDA regulations for the distribution of pharmaceutical products. However, specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed.

While specific information regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certificates is not available, Modern Drug House's partnerships with globally recognized manufacturers suggest adherence to international quality standards. The company's commitment to quality assurance and its extensive network of procurement partners further support its compliance with WHO and EU GMP guidelines.

Modern Drug House operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds an Import Export Code (IEC) of 0312031611 and FDA-approved drug licenses numbered 21B WZ 28/1609 and 20B WZ 28/1641, indicating compliance with Indian regulatory requirements. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Modern Drug House. The company's adherence to international quality standards and its partnerships with reputable manufacturers suggest a strong compliance record.

Modern Drug House operates in a competitive landscape with several key players in the pharmaceutical distribution sector. While specific market share data is not publicly available, the company's extensive network of authorized dealerships and its partnerships with multinational manufacturers position it as a significant player in the market. The company's focus on quality assurance and timely delivery further enhances its competitive edge.

Modern Drug House's key differentiators include its extensive network of authorized dealerships, partnerships with globally recognized manufacturers, and a strong commitment to quality assurance. The company's ability to source and distribute a comprehensive range of vaccines and life-saving pharmaceutical products positions it uniquely in the market.

Modern Drug House's current strategic direction focuses on expanding its global footprint through partnerships with a diverse range of manufacturers. The company's emphasis on quality assurance and timely delivery supports its strategy of becoming a trusted distributor of vaccines and pharmaceutical products worldwide. Future outlooks suggest continued growth and expansion into emerging markets, leveraging its existing network and expertise.

Modern Drug House has established a robust network of suppliers, including authorized dealerships with multinational manufacturers such as Novartis, Bharat Serum, Abbott Pvt Ltd., Chiron Panacea, Kamada Pvt Ltd., Panacea Biotech, GlaxoSmithKline, Synergy India Pvt Ltd., Serum Institute of India, VHB Life Science Pvt Ltd., John Wyeth & Brother Ltd., Bio-Med Biological Pvt. Ltd., Merck Sharp & Dohme (MSD), Bharat Biotech International Pvt. Ltd., and Sanofi Pasteur Pvt. Ltd. The company's consistent export volume and adherence to international quality standards indicate a reliable and consistent track record.

Importers should verify the following certifications when engaging with Modern Drug House:

• FDA Drug License Numbers: 21B WZ 28/1609 and 20B WZ 28/1641.

• Import Export Code (IEC): 0312031611.

These certifications can be verified through the respective regulatory bodies' official channels.

When conducting due diligence on Modern Drug House, consider the following steps:

• Verify Regulatory Certifications: Confirm FDA drug licenses and IEC through official channels.

• Assess Supplier Relationships: Evaluate the company's network of authorized dealerships and partnerships with multinational manufacturers.

• Review Quality Assurance Practices: Examine the company's quality management system and adherence to international quality standards.

• Evaluate Financial Stability: Review financial statements and assess the company's financial health.

• Check Compliance Records: Ensure there are no outstanding regulatory issues or compliance violations.

Red flags to watch for include discrepancies in certification details, lack of transparency in supplier relationships, and inconsistent quality assurance practices.